chikungunya
viru
chikv
arthropodborn
viru
arboviru
singlestrand
positivesens
rna
viru
three
genotyp
viru
alphaviru
genu
togavirida
famili
chikv
shown
infect
transmit
ae
aegyptii
ae
albopictu
mosquito
identifi
east
africa
earli
sinc
caus
epidem
continent
africa
indian
ocean
region
countri
southeast
asia
india
sinc
suspect
case
estim
million
singapor
report
outbreak
outsid
area
itali
emilia
romagna
region
small
nonepidem
import
case
report
region
north
america
franc
japan
caus
travel
return
affect
area
epidem
occur
la
reunion
island
indian
ocean
remain
devast
chikv
outbreak
onethird
popul
affect
outbreak
chikv
acquir
genet
mutat
allow
new
vector
ae
albopictu
mosquito
carri
viru
previous
chikv
circul
ae
aegyptii
mosquito
ae
albopictu
differ
suscept
variou
genet
differ
isol
viru
compar
ae
aegyptii
chikv
global
health
concern
sinc
expans
mosquito
vector
creat
potenti
chikungunya
viru
spread
temper
area
ae
albopitcu
inhabit
region
north
america
europ
chikv
infect
clinic
character
sudden
appear
high
fever
rash
headach
nausea
vomit
myalgia
arthalgia
sever
joint
pain
sever
joint
pain
defin
symptom
chikv
diseas
word
chikungunya
origin
tanzanian
mozambiqu
region
africa
mean
bend
bent
postur
often
taken
sever
joint
pain
infect
chikv
chikv
symptom
start
day
exposur
resolv
within
acut
phase
diseas
although
acut
phase
last
approxim
week
joint
pain
persist
month
year
follow
initi
infect
minim
research
done
investig
immun
respons
follow
chikv
infect
current
chikv
specif
therapeut
avail
italian
outbreak
chikv
spread
commun
surround
citi
ravenna
august
octob
also
involv
major
italian
citi
bologna
record
peopl
identifi
infect
ae
albopictu
mosquito
inhabit
emilia
romagna
region
sinc
viru
brought
emilia
romagna
region
travel
return
chikv
affect
countri
centraleast
african
genotyp
match
close
amino
acid
ident
viru
isol
reunion
island
outbreak
amino
acid
ident
confirm
viru
includ
substitut
mutat
envelop
protein
import
viral
entri
host
cell
mutat
acquir
indian
ocean
chikv
outbreak
increas
viru
infect
ae
albopictu
mosquito
cytokin
import
immun
mediat
conduct
immun
respons
recent
cytokin
profil
investig
chikv
infect
human
two
group
ng
colleagu
establish
cytokin
profil
chikv
patient
infect
singapor
chikv
outbreak
although
studi
report
rant
correl
sever
acut
phase
chikv
diseas
cytokin
profil
determin
progress
convalesc
diseas
investig
cytokin
profil
acut
phase
followup
chikv
infect
patient
italian
outbreak
sinc
chikv
diseas
sever
acut
phase
symptom
follow
persist
symptom
convalesc
phase
import
investig
immun
respons
respons
maladi
furthermor
italian
chikv
includ
mutat
singapor
viru
furthermor
analys
relationship
cytokin
level
patient
sever
igg
level
link
high
igg
level
diseas
sever
therefor
result
present
viru
specif
reflect
previous
unreport
cytokin
profil
may
import
develop
futur
therapeut
chikv
outbreak
patient
gave
written
consent
particip
scientif
studi
permiss
perform
scientif
studi
given
comitato
etico
di
area
vasta
romagna
et
irstof
servizio
sanitario
regional
emiliaromagna
itali
sinc
immun
respons
chikv
diseas
extens
investig
object
creat
clear
clinic
pictur
chikv
diseas
acut
phase
convalesc
followup
cytokin
profil
achiev
object
investig
cytokin
profil
patient
acut
phase
followup
includ
patient
region
emiliaromagna
northeast
itali
suspect
infect
chikv
sinc
show
symptom
myalgia
sever
back
joint
pain
headach
skin
rash
collabor
region
microbiolog
refer
laboratori
bologna
univers
depart
infecti
parasit
diseas
nation
institut
health
rome
initi
identifi
patient
chikv
clinic
criteria
describ
acut
onset
fever
sever
arthralgia
explain
medic
condit
chikv
infect
confirm
one
acut
phase
test
viru
isol
revers
transcriptasepcr
rtpcr
posit
chikv
gene
seroconvers
virusspecif
serum
antibodi
collect
least
week
apart
presenc
virusspecif
igm
antibodi
singl
serum
sampl
collect
acut
chikv
patient
sampl
determin
viral
stage
sampl
pcr
posit
chikv
patient
igm
antibodi
initi
stage
sampl
pcr
neg
igm
posit
igg
neg
patient
seroconvers
stage
patient
sampl
pcr
neg
igm
posit
igg
posit
sampl
consid
high
igg
igg
level
greater
month
patient
high
greater
month
patient
igg
level
equal
threshold
consid
low
igg
chikv
patient
consid
nonsymptomat
patient
followup
patient
month
followup
mild
symptom
patient
month
followup
patient
month
followup
sever
symptom
patient
month
followup
patient
month
followup
base
respons
questionnair
time
sampl
base
articular
pain
muscl
pain
monoarthr
oligoarthr
symmetr
polyarthr
asymmetr
polyarthr
tenosynov
arthralgia
fibromyalgia
control
sampl
collect
healthi
volunt
screen
symptom
viral
infect
blood
sampl
collect
consent
chikv
posit
patient
time
diagnosi
viral
infect
determin
describ
two
followup
sampl
collect
patient
evalu
evalu
sampl
serum
extract
immedi
frozen
serum
analysi
serum
sampl
analyz
cytokin
level
use
cytometr
bead
array
cba
human
chemokin
kit
human
inflammatori
cytokin
kit
human
cytokin
kit
bd
bioscienc
accord
manufactur
instruct
total
cytokin
captur
bead
ad
serum
sampl
follow
pe
detect
reagent
sampl
incub
hour
room
temperatur
wash
assay
wash
buffer
resuspend
wash
buffer
analysi
flow
cytomet
cba
run
bd
facscalibur
flow
cytomet
cba
data
analys
use
spss
statist
softwar
boxwhisk
plot
creat
cba
fac
raw
data
sixmonth
sampl
compar
acut
sampl
use
nonparametr
twotail
wilcoxon
signedrank
test
relat
sampl
determin
statist
signific
acut
phase
cytokin
sampl
set
statist
compar
healthi
control
cba
data
use
nonparametr
twotail
mann
whitney
test
unrel
sampl
chikv
caus
diseas
crippl
joint
pain
affect
asia
demonstr
capabl
spread
nontrop
area
europ
part
north
america
cytokin
inflammatori
mediat
balanc
often
associ
inflammatori
diseas
previous
cytokin
profil
acut
phase
chikv
patient
examin
profil
cytokin
level
acut
phase
followup
chikv
patient
serum
sampl
determin
cytokin
signatur
may
correl
acut
symptom
follow
persist
joint
pain
andor
diseas
resolut
blood
sampl
collect
patient
suffer
chikv
infect
italian
outbreak
serum
separ
whole
blood
analyz
cytokin
bead
analysi
cba
cytokin
intent
determin
cytokin
profil
chikv
acut
phase
diseas
convalesc
three
cytokin
profil
emerg
data
decreas
increas
notrend
first
trend
show
cytokin
level
significantli
higher
acut
sampl
compar
followup
time
point
reveal
decreas
pattern
patient
left
acut
phase
cytokin
significantli
decreas
followup
figur
interestingli
patient
extrem
high
level
acut
phase
level
decreas
fold
fold
convalesc
furthermor
decreas
trend
reach
similar
level
commun
control
level
shown
dot
line
level
decreas
significantli
lower
control
level
month
taken
togeth
data
demonstr
initi
increas
acut
chikv
infect
decreas
time
second
cytokin
trend
emerg
describ
cytokin
significantli
increas
follow
acut
phase
cytokin
profil
markedli
lower
acut
phase
subsequ
increas
includ
figur
cytokin
increas
gradual
previou
decreas
trend
fold
chang
gener
closer
followup
statist
increas
compar
acut
valu
level
significantli
increas
month
even
though
averag
cytokin
also
risen
month
signific
furthermor
increas
trend
reach
similar
level
commun
control
level
shown
dot
line
reach
significantli
higher
control
month
interestingli
although
increas
observ
time
cytokin
stay
significantli
lower
control
data
show
cytokin
increas
convalesc
phase
chikv
infect
signific
chang
seen
acut
phase
followup
figur
interestingli
reach
similar
level
control
remain
significantli
rais
lower
respect
previous
shown
acut
phase
west
nile
viru
wnv
describ
stage
sinc
sampl
chikv
patient
taken
variou
stage
acut
phase
went
determin
cytokin
mark
viral
v
igm
antibodi
initi
ai
seroconvers
sc
stage
acut
chikv
patient
sampl
determin
pcr
posit
chikv
viral
stage
igm
posit
igg
neg
igm
antibodi
initi
stage
igm
posit
igg
postiv
seroconvers
stage
sampl
put
viral
stage
v
antibodi
initi
stage
ai
seroconvers
stage
sc
accord
presenc
chikv
igm
igg
antibodi
cytokin
bead
array
analysi
serum
sampl
show
signific
decreas
viral
stage
seroconvers
stage
acut
phase
figur
median
viral
stage
approxim
pgml
drop
less
pgml
seroconvers
interestingli
median
decreas
fold
viral
stage
seroconvers
stage
next
sought
determin
high
level
igg
followup
phase
also
significantli
associ
cytokin
level
compar
cytokin
level
patient
low
level
igg
patient
put
igg
high
group
h
igg
low
group
l
level
cytokin
statist
compar
group
use
mannwhitney
u
test
followup
phase
found
statist
differ
high
igg
group
low
igg
group
figur
high
level
cytokin
associ
high
level
igg
antibodi
also
shown
comparison
sinc
statist
signific
acut
phase
breakdown
followup
interestingli
followup
phase
found
statist
higher
igg
high
group
significantli
lower
high
igg
group
figur
shown
comparison
month
although
significantli
differ
igg
high
igg
low
group
summari
result
suggest
associ
igg
level
followup
phase
followup
phase
rant
found
associ
symptom
sever
singapor
chikv
outbreak
determin
cytokin
profil
italian
chikv
patient
diseas
resolut
next
sought
determin
associ
symptom
sever
cytokin
level
patient
determin
nonsymptomat
n
mild
symptom
sever
symptom
depend
respons
questionnair
cytokin
level
group
symptom
level
mannwhitney
u
test
use
determin
signific
among
sever
group
cytokin
found
significantli
increas
patient
mild
sever
symptom
month
follow
initi
infect
compar
patient
report
symptom
figur
fold
differ
seen
median
nonsymptomat
sever
patient
fold
differ
statist
differ
seen
cytokin
profil
followup
month
shown
comparison
figur
moreov
analyz
igg
level
followup
patient
symptom
mild
symptom
sever
symptom
result
show
igg
level
statist
increas
symptom
sever
figur
taken
togeth
result
suggest
igg
possibl
marker
chikv
sever
earli
phase
diseas
resolut
chikv
diseas
selflimit
diseas
caus
alphaviru
togavirida
famili
although
histor
viru
caus
diseas
mild
symptom
recent
outbreak
la
reunion
island
caus
signific
mortal
due
genet
alter
investig
immun
respons
italian
popul
infect
indian
ocean
genotyp
chikv
gener
cytokin
signatur
initi
infect
convalesc
phase
chikv
diseas
signatur
viral
antibodi
product
phase
identifi
cytokin
rais
patient
sever
symptom
found
initi
infect
subsequ
convalesc
describ
set
decreas
increas
cytokin
furthermor
shown
level
associ
viral
stage
acut
phase
high
igg
level
followup
well
marker
symptom
sever
importantli
identifi
signatur
depict
immunolog
program
may
key
develop
therapeut
frequent
reemerg
chikv
diseas
analysi
indentifi
cytokin
profil
follow
diseas
onset
continu
diseas
progressionconvalesc
found
level
high
acut
phase
decreas
patient
convalesc
convers
trend
low
initi
increas
patient
began
recov
acut
ill
high
level
acut
phase
possibl
indic
inflammatori
program
initi
adapt
tcell
immun
chemokin
induc
part
chemokin
program
regul
migrat
monocytesmacrophag
memori
cell
nk
cell
associ
polar
cell
pleiotrop
cytokin
destruct
role
rheumatoid
arthriti
ra
contribut
joint
inflamm
well
joint
pain
increas
level
acut
phase
studi
may
initi
factor
sever
joint
pain
symptom
report
chikv
patient
mimic
ra
furthermor
import
acut
phase
diseas
act
import
immun
mediat
fever
activ
muscl
metabol
increas
core
bodi
temperatur
sinc
fever
common
symptom
acut
chikv
diseas
highli
probabl
high
level
contribut
acut
fever
decreas
trend
follow
patient
core
bodi
temperatur
return
rest
temperatur
followup
second
host
immun
respons
profil
character
increas
acut
phase
convalesc
interestingli
known
coinduc
express
involv
chronic
inflammatori
diseas
ra
chronic
hepat
b
c
infect
importantli
main
contributor
joint
pain
major
symptom
ra
intern
balanc
level
imper
misregul
either
shown
major
propon
chronic
diseas
ra
data
indic
cytokin
increas
significantli
patient
convalesc
control
group
statist
chang
patient
report
mild
sever
symptom
data
may
impli
increas
level
convalesc
phase
major
contributor
chronic
damag
caus
persist
sever
joint
pain
symptom
italian
outbreak
even
though
cytokin
previous
found
play
destruct
role
chronic
inflammatori
diseas
furthermor
immunomodul
previous
use
common
treatment
ra
immunomodul
effect
chronic
diseas
systemiconset
juvenil
idiopath
arthriti
adult
onset
still
diseas
taken
togeth
find
suggest
therapi
would
effect
control
prolong
symptom
chikv
diseas
sinc
rais
level
convalesc
associ
patient
sever
previous
cytokin
profil
analyz
patient
asian
outbreak
chikv
ng
colleagu
investig
cytokin
growth
factor
acut
phase
chikv
patient
determin
level
cytokin
chemokin
growth
factor
significantli
rais
patient
compar
control
group
accord
data
also
increas
acut
phase
patient
compar
control
sinc
result
previou
studi
follow
patient
convalesc
studi
ad
signific
insight
progress
chikv
diseas
found
three
cytokin
level
decreas
patient
convalesc
discuss
convers
found
also
increas
acut
phase
compar
control
group
unchang
ng
studi
furthermor
ng
et
al
found
significantli
increas
acut
phase
data
indic
initi
low
control
level
increas
follow
acut
phase
discrep
possibl
explain
patient
popul
ng
studi
patient
patient
significantli
vari
genet
background
asian
european
respect
therefor
differ
immun
respons
may
reflect
variat
immunolog
genet
program
well
viru
caus
two
outbreak
also
differ
genet
even
though
viru
caus
singapor
outbreak
genotyp
italian
viru
viru
infect
italian
patient
mutat
gene
acquir
la
reunion
island
although
impact
mutat
shown
increas
vector
infect
mutat
investig
human
mammalian
immun
respons
previous
identifi
stage
acut
phase
wnv
viral
stage
antibodi
initi
stage
seroconvers
stage
viral
load
decreas
wnv
patient
igm
antibodi
level
initi
follow
igm
convers
igg
therebi
mark
stage
acut
phase
work
abl
identifi
stage
chikv
patient
compar
respect
serum
cytokin
level
found
level
decreas
patient
progress
viral
stage
seroconvers
sinc
often
correl
viral
load
observ
surpris
high
level
viral
stage
may
act
effort
control
program
shown
high
level
furthermor
plasma
level
well
correl
viral
load
viru
infect
individu
possibl
decreas
observ
subsequ
acut
phase
correl
viral
clearanc
although
antibodi
level
analysi
cytokineantibodi
respons
carri
followup
group
patient
igg
level
rais
patient
increas
igg
level
month
followup
proinflammatori
cytokin
associ
high
igg
level
may
repres
persist
activ
immun
system
well
high
igg
level
found
biomark
sever
chikv
symptom
previous
associ
sever
viral
diseas
support
role
sever
chikv
diseas
studi
find
associ
sever
seen
chikv
patient
find
suggest
high
associ
sever
uniqu
signatur
chikv
interestingli
express
ra
arthriti
relat
diseas
patient
shown
biomark
ra
symptom
impli
similar
mechan
joint
destruct
chikv
diseas
moreov
may
contributor
persist
immun
activ
chikv
diseas
lead
chronic
symptom
impli
cytokin
immunomodul
may
significantli
improv
patient
treatment
recoveri
importantli
also
prognost
valu
treatment
viral
hepat
level
follow
diseas
recoveri
support
find
propos
prognost
role
chikv
furthermor
data
put
forth
possibl
drug
target
treatment
chikv
symptom
convalesc
phase
due
associ
sever
howev
investig
need
efficaci
addit
identifi
cytokin
use
possibl
drug
target
cytokin
signatur
describ
also
appli
test
newli
develop
chikv
therapeut
chikv
therapeut
evalu
chikv
diseas
model
cytokin
profil
use
output
determin
efficaci
novel
therapeut
synovi
mast
cell
remain
import
compon
ra
joint
destruct
exocytosi
intracellular
granul
contain
inflammatori
mediat
current
mast
cell
activ
high
level
circul
igg
antibodi
hypothes
contribut
patholog
destruct
synovium
ra
addit
antibodi
immun
complex
format
within
joint
stabil
inflammatori
mediat
chemokin
complement
protein
anoth
possibl
facet
pathogenesi
ra
found
high
concentr
igg
associ
symptom
sever
chikv
patient
similar
igg
mediat
mechan
lead
synovium
destruct
sever
pain
experienc
chikv
patient
possibl
taken
togeth
role
igg
ra
find
support
need
investig
contribut
igg
level
mast
cell
chikv
symptom
found
cytokin
investig
one
two
immunolog
import
profil
chikv
diseas
onset
convalesc
furthermor
maker
diseas
sever
identifi
immun
profil
creat
clearer
clinic
pictur
chikv
diseas
importantli
investig
need
correl
profil
diseas
onset
progress
use
cytokin
profil
biomark
sever
symptom
persist
data
present
suggest
investig
immunomodul
may
significantli
enhanc
patient
recoveri
